Other relevant studies demonstrated that the co-mutation of TP53 and KRAS led to an immune-rich microenvironment of high tumor mutation burden (TMB), enhanced PD-L1 expression, and enrichment of immune cell infiltration, namely, CD4 memory T cells, NK cells, and M1 macrophages. This evidence concerns the gene KRAS and neoplasm.